Vergent Bioscience

Vergent Bioscience is a private, clinical-stage biotech developing VGT-309, a targeted fluorescent imaging agent that illuminates tumors during surgery by binding to cathepsin proteases. The company is currently running a Phase 2b study in lung cancer to help surgeons remove all tumor tissue, particularly in minimally invasive and robotic-assisted procedures. By addressing a critical unmet need in surgical oncology, Vergent aims to improve surgical outcomes and establish itself as a leader in intraoperative tumor visualization. The technology platform has the potential for application across multiple solid tumor types.

Tumor-targeted, activatable fluorescent imaging agents that bind covalently to cathepsin proteases overexpressed in solid tumors. The platform uses a quenched activity-based probe (qABP) design with the near-infrared dye Indocyanine Green (ICG), which fluoresces only upon enzyme binding, providing high tumor-to-background signal. It is compatible with all commercial NIR intraoperative imaging systems.

Competition includes non-targeted NIR dyes like ICG (used off-label) and other targeted fluorescent probes in development (e.g., those targeting folate receptors or other enzymes). Larger medical device companies (e.g., Intuitive Surgical, Stryker) and pharma giants with oncology focus could enter the space. Vergent's key differentiator is its activatable, covalent cathepsin-targeting mechanism designed for high specificity and sustained signal during surgery.